P2RY13 is a G protein-coupled purinergic receptor for ADP that functions as a key regulator of inflammatory and immune responses across multiple disease contexts. 1 Mechanistically, P2RY13 exacerbates intestinal inflammation by damaging the intestinal mucosal barrier through activation of the IL-6/STAT3 signaling pathway, and pharmacological antagonism of P2RY13 significantly attenuates colitis development in mice. 1 In aging-related pathology, P2RY13 expression is downregulated in aged microglia, correlating with diminished microglial immune responsiveness and altered purine sensing capacity. 2 P2RY13 serves as a shared biomarker in multiple metabolic and cardiovascular diseases: it is downregulated in lung adenocarcinoma and associated with pro-tumor immune effects, 3 identified as a hub gene predicting atherosclerosis progression in polycystic ovary syndrome patients, 4 and emerging as a shared hub gene linking type 2 diabetes and atherosclerosis through macrophage dysregulation. 5 Additionally, P2RY13 transcript dysregulation in blood correlates with Machado-Joseph disease severity, 6 and its downregulation associates with ovarian cancer metastasis. 7 P2RY13 is also identified as a key gene shared between obesity and periodontitis, linked to macrophage activity and immune regulation. 8 These findings position P2RY13 as a potential therapeutic target in inflammatory, neurodegenerative, and malignant diseases.